These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 35786664)

  • 1. β-catenin plus PROX1 immunostaining stratifies disease progression and patient survival in neoadjuvant-treated pancreatic cancer.
    Eurola A; Ristimäki A; Mustonen H; Nurmi AM; Hagström J; Kallio P; Alitalo K; Haglund C; Seppänen H
    Tumour Biol; 2022; 44(1):69-84. PubMed ID: 35786664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.
    Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Kallio P; Alitalo K; Seppänen H; Haglund C
    BMC Cancer; 2016 Jul; 16():472. PubMed ID: 27411302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer.
    Eurola A; Ristimäki A; Mustonen H; Nurmi AM; Hagström J; Haglund C; Seppänen H
    Sci Rep; 2021 May; 11(1):9896. PubMed ID: 33972616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positive regulation of β-catenin-PROX1 signaling axis by DBC1 in colon cancer progression.
    Yu EJ; Kim SH; Kim HJ; Heo K; Ou CY; Stallcup MR; Kim JH
    Oncogene; 2016 Jun; 35(26):3410-8. PubMed ID: 26477307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PROX1 promotes hepatocellular carcinoma proliferation and sorafenib resistance by enhancing β-catenin expression and nuclear translocation.
    Liu Y; Ye X; Zhang JB; Ouyang H; Shen Z; Wu Y; Wang W; Wu J; Tao S; Yang X; Qiao K; Zhang J; Liu J; Fu Q; Xie Y
    Oncogene; 2015 Oct; 34(44):5524-35. PubMed ID: 25684142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complementary Wnt Sources Regulate Lymphatic Vascular Development via PROX1-Dependent Wnt/β-Catenin Signaling.
    Cha B; Geng X; Mahamud MR; Zhang JY; Chen L; Kim W; Jho EH; Kim Y; Choi D; Dixon JB; Chen H; Hong YK; Olson L; Kim TH; Merrill BJ; Davis MJ; Srinivasan RS
    Cell Rep; 2018 Oct; 25(3):571-584.e5. PubMed ID: 30332639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Effectiveness of Neoadjuvant Therapy and Upfront Resection for Patients with Resectable Pancreatic Adenocarcinoma: An Instrumental Variable Analysis.
    da Costa WL; Tran Cao HS; Sheetz KH; Gu X; Norton EC; Massarweh NN
    Ann Surg Oncol; 2021 Jun; 28(6):3186-3195. PubMed ID: 33174146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperglycemia Promotes Pancreatic Cancer Initiation and Progression by Activating the Wnt/β-Catenin Signaling Pathway.
    Chen H; Zhao J; Jiang N; Wang Z; Liu C
    Anticancer Agents Med Chem; 2021; 21(18):2592-2602. PubMed ID: 33563184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of WNT/β-Catenin Signaling Enhances Pancreatic Cancer Development and the Malignant Potential Via Up-regulation of Cyr61.
    Sano M; Driscoll DR; DeJesus-Monge WE; Quattrochi B; Appleman VA; Ou J; Zhu LJ; Yoshida N; Yamazaki S; Takayama T; Sugitani M; Nemoto N; Klimstra DS; Lewis BC
    Neoplasia; 2016 Dec; 18(12):785-794. PubMed ID: 27889647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study.
    Lof S; Korrel M; van Hilst J; Alseidi A; Balzano G; Boggi U; Butturini G; Casadei R; Dokmak S; Edwin B; Falconi M; Keck T; Malleo G; de Pastena M; Tomazic A; Wilmink H; Zerbi A; Besselink MG; Abu Hilal M;
    Ann Surg Oncol; 2020 Jun; 27(6):1986-1996. PubMed ID: 31848815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PROX1 promotes breast cancer invasion and metastasis through WNT/β-catenin pathway via interacting with hnRNPK.
    Zhu L; Tian Q; Gao H; Wu K; Wang B; Ge G; Jiang S; Wang K; Zhou C; He J; Liu P; Ren Y; Wang B
    Int J Biol Sci; 2022; 18(5):2032-2046. PubMed ID: 35342346
    [No Abstract]   [Full Text] [Related]  

  • 12. Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis.
    Deng A; Wang C; Cohen SJ; Winter JM; Posey J; Yeo C; Basu Mallick A
    Eur J Cancer; 2021 Apr; 147():17-28. PubMed ID: 33607382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy.
    Hank T; Sandini M; Ferrone CR; Rodrigues C; Weniger M; Qadan M; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
    JAMA Surg; 2019 Oct; 154(10):943-951. PubMed ID: 31411659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer.
    Murthy P; Zenati MS; Al Abbas AI; Rieser CJ; Bahary N; Lotze MT; Zeh HJ; Zureikat AH; Boone BA
    Ann Surg Oncol; 2020 Mar; 27(3):898-906. PubMed ID: 31792715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morphologic changes associated with neoadjuvant-treated pancreatic ductal adenocarcinoma and comparison of two tumor regression grading systems.
    Vazzano J; Frankel WL; Wolfe AR; Williams TM; Chen W
    Hum Pathol; 2021 Mar; 109():1-11. PubMed ID: 33245985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
    Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
    J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The expression and prognostic value of toll-like receptors (TLRs) in pancreatic cancer patients treated with neoadjuvant therapy.
    Nurmi AM; Hagström J; Mustonen H; Seppänen H; Haglund C
    PLoS One; 2022; 17(5):e0267792. PubMed ID: 35536778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Knockdown of FOXO3a induces epithelial-mesenchymal transition and promotes metastasis of pancreatic ductal adenocarcinoma by activation of the β-catenin/TCF4 pathway through SPRY2.
    Li J; Yang R; Dong Y; Chen M; Wang Y; Wang G
    J Exp Clin Cancer Res; 2019 Jan; 38(1):38. PubMed ID: 30691517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of Hospital Neoadjuvant Therapy Utilization on Survival Outcomes for Pancreatic Cancer.
    Fisher AV; Abbott DE; Venkatesh M; Leverson GE; Campbell-Flohr SA; Ronnekleiv-Kelly SM; Greenberg CC; Winslow ER; Weber SM
    Ann Surg Oncol; 2018 Sep; 25(9):2661-2668. PubMed ID: 30003452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histological tumor necrosis in pancreatic cancer after neoadjuvant therapy.
    Kudo M; Ishii G; Gotohda N; Konishi M; Takahashi S; Kobayashi S; Sugimoto M; Martin JD; Cabral H; Kojima M
    Oncol Rep; 2022 Jul; 48(1):. PubMed ID: 35583018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.